US panel rejects Debiovision's Sanvar for oesophageal bleeding
This article was originally published in Scrip
Executive Summary
Citing a lack of efficacy evidence, a US FDA advisory panel recommended against approval of Debiovision's somatostatin analogue Sanvar (vapreotide acetate) injection for controlling acute oesophageal variceal bleeding (OVB).